Elanco 8-K: Press release with full-year and Q4 2025 guidance

Rhea-AI Filing Summary

Elanco Animal Health (ELAN) furnished a Current Report announcing results for the fiscal quarter ended September 30, 2025, along with guidance for the full year and fourth quarter of 2025. The details are provided in a press release attached as Exhibit 99.1, dated November 5, 2025.

The Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/05/2025 - 06:30 AM Learn about SEC filing dates

FAQ

What did Elanco (ELAN) report in this 8-K?

It furnished a press release announcing results for the quarter ended September 30, 2025, and guidance for the full year and fourth quarter of 2025.

Which exhibit contains the earnings press release for ELAN?

The press release is attached as Exhibit 99.1.

Is the information in this 8-K considered filed or furnished?

The Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed under the Exchange Act.

What period do the reported results cover for ELAN?

The fiscal quarter ended September 30, 2025.

Does the filing include guidance for ELAN?

Yes. It includes guidance for the full year 2025 and the fourth quarter of 2025.

What is Elanco’s trading symbol and exchange?

Elanco trades as ELAN on the New York Stock Exchange.

FALSE000173910400017391042025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________

Form 8-K

_______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

Elanco Animal Health Incorporated

(Exact name of Registrant as specified in its charter)

INDIANA

001-38661

82-5497352

(State or other jurisdiction of

(Commission File

(I.R.S. Employer

incorporation)

Number)

Identification No.)

450 ELANCO CIRCLE						46221
INDIANAPOLIS, INDIANA						(Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code: (877) 352-6261

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, no par value			ELAN			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations or Financial Condition.

Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated November 5, 2025, announcing the results of operations for the fiscal quarter ended September 30, 2025, and guidance for the full year and fourth quarter of 2025, for Elanco Animal Health Incorporated.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

			Exhibit Number						Description
			99.1						Press Release issued by Elanco Animal Health Incorporated dated November 5, 2025
			104.1						Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						ELANCO ANIMAL HEALTH INCORPORATED
Date:			November 5, 2025			/s/ Robert M. VanHimbergen
						Robert M. VanHimbergen
						Executive Vice President and Chief Financial Officer